Plant transient expression offers a flexible approach in drug development and enables rapid production and scale up of therapeutics.
Plant transient expression offers a flexible approach in drug development and enables rapid production and scale up of therapeutics.
Download the BioPharm International
Bioprocessing Trends 2016 eBook.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.